Drug monitoring in systemic lupus erythematosus
Current opinion in pharmacology · 2022 Jun
Abstract
Therapeutic drug monitoring (TDM) is not yet accepted by systemic lupus erythematosus (SLE) treatment guidelines. Studies in SLE, however, have proven benefit in three areas: identification of non-adherence or poor adherence; targets for clinical benefit; and ranges of toxicity. This review covers the data on three medications commonly used for SLE, drawing on studies from both the SLE and non-SLE literature.
Neurotransmitters
None linked yet.
Related
Community votes: 0
Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —
Community
Log in to rate and share your notes.
No contributions yet.